Meeting
2012 ASCO Annual Meeting
Ipilimumab-induced hypophysitis in melanoma patients.
Authors
Typhanie Carré
Dermatology Department, Timone Hospital, Aix Marseille University, Marseille, France
Typhanie Carré , Caroline Gaudy-Marqueste , Frédérique Albarel , Sandrine Monestier , Stéphanie Mallet , Thierry Brue , Marie-Aleth Richard , Jean Jacques Grob
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Melanoma
Citation
J Clin Oncol 30, 2012 (suppl; abstr 8568)
DOI
10.1200/jco.2012.30.15_suppl.8568
Abstract #
8568
Poster Bd #
35B
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
One-year overall survival (OS) and biomarker correlates from a phase II study of ipilimumab (IPI) with carboplatin and paclitaxel (CP) in patients with unresectable stage III or IV metastatic melanoma (MM).
First Author: Rahima Jamal
Poster
2013 ASCO Annual Meeting
Pretreatment levels of absolute and relative eosinophil count to improve overall survival (OS) in patients with metastatic melanoma under treatment with ipilimumab, an anti CTLA-4 antibody.
First Author: Katja Schindler
Poster
2023 ASCO Annual Meeting
CHARLI: A phase Ib/II trial of ipilimumab-nivolumab-denosumab or nivolumab-denosumab in patients with unresectable stage III and IV melanoma.
First Author: Peter Kar Han Lau
Poster
2021 ASCO Annual Meeting
Toxicity, response, and survival in older adults with metastatic melanoma treated with checkpoint inhibitors.
First Author: Nienke A De Glas